MBRX · Moleculin Biotech, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $5.38M | - | $3.74M | $3.60M | $3.44M | - | $4.93M | $4.09M | $4.25M | - |
| SG&A | $2.49M | - | $2.15M | $2.09M | $2.48M | - | $2.17M | $2.06M | $2.39M | - |
| Total Operating Expenses | $7.87M | - | $5.91M | $5.72M | $5.94M | - | $7.13M | $6.18M | $6.68M | - |
| D&A | $8.0K | - | $21.0K | $29.0K | $31.0K | - | $31.0K | $31.0K | $32.0K | - |
| Operating Income | ($7.87M) | - | ($5.91M) | ($5.72M) | ($5.94M) | - | ($7.13M) | ($6.18M) | ($6.68M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($12.85M) | - | ($25.40M) | ($7.64M) | ($6.44M) | - | ($10.59M) | ($4.32M) | ($4.97M) | - |
| EPS - Basic | ($3.54) | - | ($17.00) | ($12.25) | ($17.25) | - | ($71.25) | ($42.50) | ($50.50) | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.32M | $8.88M | $6.70M | $7.56M | $7.72M | $4.28M | $9.40M | $10.85M | $16.82M | $23.55M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.57M | $3.51M | $2.12M | $3.72M | $2.71M | $2.03M | $2.55M | $2.83M | $2.10M | $2.50M |
| Current Assets | $10.96M | $9.69M | $7.88M | $9.08M | $9.34M | $5.19M | $11.61M | $13.73M | $18.96M | $26.27M |
| Total Assets | $23.36M | $22.13M | $20.35M | $21.59M | $21.01M | $16.93M | $23.39M | $25.57M | $30.84M | $38.22M |
| Current Liabilities | $7.96M | $6.85M | $5.68M | $7.91M | $6.90M | $5.36M | $5.59M | $5.75M | $5.41M | $6.82M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $8.18M | $7.12M | $47.27M | $28.76M | $20.97M | $10.95M | $15.91M | $7.87M | $9.26M | $12.14M |
| Stockholders' Equity | $15.18M | $15.01M | ($26.92M) | ($7.17M) | $42.0K | $5.98M | $7.48M | $17.70M | $21.59M | $26.07M |
| Retained Earnings | ($218.85M) | ($206.00M) | ($221.56M) | ($167.44M) | ($159.80M) | ($153.37M) | ($151.49M) | ($140.89M) | ($136.57M) | ($131.60M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($6.11M) | - | - | - | ($4.56M) | - | - | - | ($6.72M) | - |
| Investing Cash Flow | $0 | - | - | - | $0 | - | - | - | - | - |
| Financing Cash Flow | $7.61M | - | - | - | $8.00M | - | - | - | $0 | - |
| CapEx | - | - | - | - | $0 | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | ($4.56M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 0.71 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -55.0% | - | -124.8% | -35.4% | -30.6% | - | -45.3% | -16.9% | -16.1% | - |
| Return on equity | -84.6% | - | 94.3% | 106.6% | -15323.8% | - | -141.6% | -24.4% | -23.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.38 | 1.41 | 1.39 | 1.15 | 1.35 | 0.97 | 2.08 | 2.39 | 3.51 | 3.86 |
| Quick ratio | 1.38 | 1.41 | 1.39 | 1.15 | 1.35 | 0.97 | 2.08 | 2.39 | 3.51 | 3.86 |
| Cash ratio | 1.30 | 1.30 | 1.18 | 0.96 | 1.12 | 0.80 | 1.68 | 1.89 | 3.11 | 3.46 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.54 | 1.47 | -0.76 | -3.01 | 500.31 | 2.83 | 3.13 | 1.44 | 1.43 | 1.47 |
| Liabilities / Assets | 0.35 | 0.32 | 2.32 | 1.33 | 1.00 | 0.65 | 0.68 | 0.31 | 0.30 | 0.32 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -32.5% | - | 17.2% | 7.5% | 11.0% | - | -20.0% | 3.5% | 20.1% | - |
| Net income growth (YoY) | -99.6% | - | -139.8% | -76.9% | -29.5% | - | -88.8% | 27.7% | 37.2% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 36050.0% | 151.0% | - | - | -99.8% | -77.1% | -78.7% | -56.0% | -52.7% | -50.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Moleculin Biotech against the 5 most active filers in the same SIC group.